Alnylam Pharmaceuticals, Inc. (alny)

Unlock full data in Terminal →

ALNY — Company Overview

Alnylam Pharmaceuticals, Inc. (ALNY) is a large-cap company in the Healthcare sector, operating in Biotechnology.

Ticker	ALNY
Sector	Healthcare
Industry	Biotechnology
Exchange	NMS
Market cap	$32.99B
Last price	$246.51
Size category	Large Cap

ALNY — Business Description

Alnylam Pharmaceuticals, Inc. (ALNY) operates in Biotechnology within the broader Healthcare market. Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus…

Official website: https://www.alnylam.com.

ALNY — Investment Thesis

The investment thesis for Alnylam Pharmaceuticals, Inc. (ALNY) rests on how Healthcare dynamics, profitability, and valuation interact at today's price.

Revenue is expanding at roughly 66.9% year-over-year (public data).
Trailing P/E of 43.86× implies elevated growth expectations at the current price.
Forward P/E (19.77×) is below trailing P/E — earnings may be expected to improve.
Equity market capitalization is approximately $32.99B.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

ALNY — Financial Health

Financial health for Alnylam Pharmaceuticals, Inc. (ALNY) is summarized from publicly reported profitability, leverage, and cash-flow metrics.

Profit margin of 16.1% indicates solid bottom-line conversion. Positive free cash flow of $271.54M supports balance-sheet flexibility. Debt-to-equity of 220.62 warrants monitoring in a higher-rate environment.

Trailing P/E	43.86×
Forward P/E	19.77×
Price / Sales	6.87×
Price / Book	24.35×
Gross margin	79.7%
Operating margin	17.9%
Profit margin	16.1%
Return on equity	96.6%
Debt / Equity	220.62
Free cash flow	$271.54M

ALNY — Growth Outlook

Growth outlook for Alnylam Pharmaceuticals, Inc. (ALNY) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.

Revenue growth of 66.9% indicates strong top-line momentum.
Price is 50.3% below the 52-week high.
Shares trade 24.6% above the 52-week low — limited rebound so far.

ALNY — Competitive Position

Alnylam Pharmaceuticals, Inc. (ALNY) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

Competes within Healthcare, specifically in Biotechnology.
Market capitalization of $32.99B places ALNY among large-cap peers.
Gross margin near 79.7% may reflect pricing power or favorable mix.

ALNY — Strengths

Strengths for Alnylam Pharmaceuticals, Inc. (ALNY) inferred from public financial metrics:

Revenue growth of 66.9% year-over-year.
Return on equity near 96.6% — efficient use of shareholder capital.
Gross margin of 79.7% supports competitive unit economics.
Positive free cash flow ($271.54M).
Large Cap scale ($32.99B) may provide distribution and funding advantages.

ALNY — Weaknesses

Weaknesses and pressure points for Alnylam Pharmaceuticals, Inc. (ALNY) based on available data:

Elevated trailing P/E (43.86×) limits valuation margin of safety.
Elevated debt-to-equity (220.62).
Price 50% below the 52-week high — sustained negative sentiment.

ALNY — Opportunities

Sustained revenue growth (66.9%) could support multiple expansion if margins hold.
Trading 24.6% above the 52-week low — potential recovery if fundamentals stabilize.
Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.

ALNY — Risks

Rich valuation (P/E 43.86×) increases downside if growth slows.
Leverage (debt/equity 220.62) raises sensitivity to credit conditions.

ALNY — Summary

Alnylam Pharmaceuticals, Inc. (ALNY) is a large-cap Healthcare company focused on Biotechnology, listed on NMS. Last price $246.51 with market cap $32.99B. Trailing P/E 43.86×. Revenue grew 66.9% year-over-year per public data. Notable strengths include revenue growth of 66.9% year-over-year. Key watch items include elevated trailing p/e (43.86×) limits valuation margin of safety. Public estimates and earnings snapshots for Alnylam Pharmaceuticals, Inc. are on this site; ownership, live news, and deeper models remain in Vest Terminal.

Start Free — open ALNY in Vest Terminal

Access live data, filings, ownership, and analysis for Alnylam Pharmaceuticals, Inc..

Create free account See plans

Alnylam Pharmaceuticals, Inc. FAQ

What does Alnylam Pharmaceuticals, Inc. (ALNY) do?

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUT…

What is ALNY's P/E ratio?

Alnylam Pharmaceuticals, Inc. has a trailing P/E of 43.86× based on publicly available market data.

Does ALNY pay a dividend?

Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.

What sector is ALNY in?

Alnylam Pharmaceuticals, Inc. is classified in Healthcare (Biotechnology) on NMS.

What is ALNY's market capitalization?

Approximate market cap: $32.99B.

What are the main risks for ALNY?

Key risks include elevated valuation, among factors on this page.

What are the strengths of ALNY?

Potential positives include revenue growth of 66.9% year-over-year, return on equity near 96.6% — efficient use of shareholder capital.

Where can I get analyst estimates for ALNY?

Public analyst price targets and consensus for Alnylam Pharmaceuticals, Inc. are on the free /stocks/alny/estimates page. Deeper estimate history and models are available in Vest Terminal.